Skip to search formSkip to main contentSkip to account menu

ICRF 154

Known as: ICRF-154 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
After the identification of a new lead bisphenol compound that had good topoisomerase IIα (EC 5.99.1.3) inhibitory activity, a… 
Highly Cited
2001
Highly Cited
2001
The bisdioxopiperazines ICRF-187 (dexrazoxane), ICRF-193, and ICRF-154 are catalytic noncleavable complex-forming inhibitors of… 
1997
1997
Histologic and biochemical studies were carried out to compare the protective activity of various bisdiketopiperazines against… 
1992
1992
We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were… 
Highly Cited
1991
Highly Cited
1991
Several recently developed derivatives of bis(2,6-dioxopiperazine) have been shown to be new antitumor agents and are currently… 
Highly Cited
1991
Highly Cited
1991
In the accompanying paper (K. Tanabe, Y. Ikegami, R. Ishida, and T. Andoh, Cancer Res., 51: 4903-4908, 1991), we showed that ICRF…